Literature DB >> 16439124

Beta-diketo acids with purine nucleobase scaffolds: novel, selective inhibitors of the strand transfer step of HIV integrase.

Vasu Nair1, Vinod Uchil, Nouri Neamati.   

Abstract

The HIV pol gene encodes three viral enzymes that are required for its replication. While drug discovery involving the viral targets, reverse transcriptase and protease, has resulted in useful therapeutic agents, such efforts on HIV integrase have not produced a single FDA-approved drug. In the work focused on the discovery of inhibitors of HIV integrase, we have synthesized new beta-diketo acids with purine nucleobase scaffolds that are potent inhibitors of the strand transfer steps of wild-type HIV-1 integrase.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16439124     DOI: 10.1016/j.bmcl.2005.12.093

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  4 in total

1.  A novel diketo phosphonic acid that exhibits specific, strand-transfer inhibition of HIV integrase and anti-HIV activity.

Authors:  Guochen Chi; Vasu Nair; Elena Semenova; Yves Pommier
Journal:  Bioorg Med Chem Lett       Date:  2006-12-15       Impact factor: 2.823

2.  A novel strategy to assemble the beta-diketo acid pharmacophore of HIV integrase inhibitors on purine nucleobase scaffolds.

Authors:  Vinod Uchil; Byung Seo; Vasu Nair
Journal:  J Org Chem       Date:  2007-10-05       Impact factor: 4.354

3.  Hybrid quantum mechanical/molecular mechanical molecular dynamics simulations of HIV-1 integrase/inhibitor complexes.

Authors:  Nadtanet Nunthaboot; Somsak Pianwanit; Vudhichai Parasuk; Jerry O Ebalunode; James M Briggs; Sirirat Kokpol
Journal:  Biophys J       Date:  2007-08-10       Impact factor: 4.033

Review 4.  Integrase Inhibitor Prodrugs: Approaches to Enhancing the Anti-HIV Activity of β-Diketo Acids.

Authors:  Vasu Nair; Maurice Okello
Journal:  Molecules       Date:  2015-07-13       Impact factor: 4.411

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.